| Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study W Ghusn, S Fansa, D Anazco, E Tama, B Nicolalde, K Gala, A De la Rosa, ... International Journal of Obesity, 1-6, 2024 | 6 | 2024 |
| The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes W Ghusn, S Fansa, D Anazco, E Tama, L Cifuentes, K Gala, ... Diabetes, Obesity and Metabolism 26 (6), 2167-2175, 2024 | 4 | 2024 |
| Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use MD Hurtado, E Tama, S Fansa, W Ghusn, D Anazco, A Acosta, ... Menopause, 10.1097, 2023 | 3 | 2023 |
| Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score W Ghusn, D Anazco, S Fansa, E Tama, L Cifuentes, K Gala, G Calderon, ... Eclinicalmedicine 72, 2024 | 2 | 2024 |
| Type 2 Diabetes Remission in Patients with Heterozygous Variants in the Leptin-Melanocortin Pathway after Roux-en-Y Gastric Bypass: A Matched Case–Control Study D Anazco, W Ghusn, A Campos, L Cifuentes, S Fansa, E Tama, JT Bublitz, ... Obesity Surgery 33 (11), 3502-3509, 2023 | 2 | 2023 |
| FRI077 Efficacy of anti-obesity medications among breast cancer survivors taking aromatase inhibitors S Fansa, W Ghusn, E Tama, B Nicolalde, D Anazco, S D'Andre, S Faubion, ... Journal of the Endocrine Society 7 (Supplement_1), bvad114. 087, 2023 | 2 | 2023 |
| 638 PERFORMANCE OF A MACHINE-LEARNING GENE RISK SCORE BIOMARKER ON PREDICTING RESPONSE TO SEMAGLUTIDE: A PROSPECTIVELY FOLLOWED MULTI-CENTER BIOBANK AND OUTCOMES REGISTRY S Fansa, E Tama, D Anazco, L Cifuentes, W Ghusn, K Gala, E Kolkin, ... Gastroenterology 166 (5), S-148, 2024 | 1 | 2024 |
| Cumulative effect of obesity phenotypes on body weight and body mass index W Ghusn, L Cifuentes, D Anazco, S Fansa, E Tama, A Campos, K Gala, ... International Journal of Obesity, 1-7, 2024 | 1 | 2024 |
| Severe insulin resistance in a patient treated with nivolumab and brentuximab-vedotin for Hodgkin lymphoma E Tama, M Black, MA Moustafa, MD Hurtado JCEM Case Reports 1 (6), luad121, 2023 | 1 | 2023 |
| Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks S Thota-Kammili, E Tama, MD Hurtado Andrade Current Treatment Options in Gastroenterology 22 (3), 145-154, 2024 | | 2024 |
| Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet: A Retrospective Matched Cohort Study D Anazco, S Fansa, W Ghusn, K Gala, B Nicolalde, E Tama, G Calderon, ... Journal of clinical gastroenterology 58 (7), 650-655, 2024 | | 2024 |
| Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors S Fansa, W Ghusn, E Tama, B Nicolalde, D Anazco, SD Andre, ... Breast Cancer Research and Treatment, 1-11, 2024 | | 2024 |
| 1660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes—The Mayo Clinic Experience E TAMA, D BECHENATI, P BENNETT, A MCNALLY, R RIVERA, S FANSA, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience S FANSA, E TAMA, N SAFWAN, W GHUSN, D ANAZCO, A ACOSTA, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 234-OR: Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide E TAMA, S FANSA, D ANAZCO, R RIVERA, W GHUSN, L CIFUENTES, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| Sa1951 CLINICAL PARAMETERS ASSOCIATED WITH SEMAGLUTIDE INTOLERANCE IN PATIENTS WITH DIABETES AND OBESITY W Ghusn, D Anazco, S Fansa, E Tama, L Cifuentes, A Campos, K Gala, ... Gastroenterology 166 (5), S-591-S-592, 2024 | | 2024 |
| 1283 SATIATION TESTING AND A SURROGATE MACHINE-LEARNING ASSISTED GENE RISK SCORE BIOMARKER PREDICT DIFFERENTIAL RESPONSES TO LIFESTYLE INTERVENTIONS: A POST-HOC ANALYSIS OF A … D Anazco, L Cifuentes, S Fansa, W Ghusn, A Campos, E Tama, K Gala, ... Gastroenterology 166 (5), S-306-S-307, 2024 | | 2024 |
| ORIGINAL STUDY MD Hurtado, E Tama, S Fansa, W Ghusn Menopause 31 (4), 2024 | | 2024 |
| The Relation Between Excess Adiposity and Breast Cancer in Women: Clinical Implications and Management MD Hurtado, E Tama, S D’Andre, C Shufelt Critical Reviews in Oncology/Hematology, 104213, 2023 | | 2023 |
| Weight Loss Response to Semaglutide in Menopausal Women with and without Menopausal Hormone Therapy E Tama, W Ghusn, S Fansa, D Anazco, S Faubion, C Shufelt, A Acosta, ... OBESITY 31, 169-169, 2023 | | 2023 |
